Earnings Call Summary | IRIDEX(IRIX.US) Q4 2023 Earnings Conference
Earnings Call Summary | IRIDEX(IRIX.US) Q4 2023 Earnings Conference
The following is a summary of the IRIDEX Corporation (IRIX) Q4 2023 Earnings Call Transcript:
以下是IRIDEX公司(IRIX)2023年第四季度财报电话会议记录的摘要:
Financial Performance:
财务业绩:
IRIDEX reported full-year revenue of $51.9 million in 2023, with Q4 revenue reaching $12.5 million.
The company experienced a net loss of $3 million in Q4, a decrease from $1.1 million in the previous year due to factors including reimbursement restrictions in the US and supply chain limitations.
The Q4 gross profit was $4.9 million, compared to $6.7 million in the same period of the previous year.
The company managed to reduce its Q4 net cash to the lowest in 2023 through cost-cutting measures.
IRIDEX报告称,2023年全年收入为5190万美元,第四季度收入达到1,250万美元。
由于美国的报销限制和供应链限制等因素,该公司在第四季度净亏损300万美元,低于去年的110万美元。
第四季度的毛利为490万美元,而去年同期为670万美元。
通过削减成本的措施,该公司设法将其第四季度的净现金减少到2023年的最低水平。
Business Progress:
业务进展:
Despite the challenges, IRIDEX made strong progress in the glaucoma segment with significant presence at the World Glaucoma Congress.
The company expanded its clinical evidence base and increased utilization by launching a registry program in the UK.
FDA clearance was received for their new single spot platform for the IRIDEX 532 and 577 systems, strengthening their position in retina treatment.
They are strategizing to drive utilization across their existing installed base and build adoption among moderate-stage glaucoma patients.
In 2024, with improved business flows and resolved supply chain issues, the company anticipates a return to more normalized levels.
The company positioned itself for recovery as two new platforms were developed in the retina segment, with notable interest in the new IRIDEX PASCAL platform.
尽管面临挑战,IRIDEX在青光眼领域取得了长足的进展,并在世界青光眼大会上大放异彩。
该公司通过在英国启动注册计划,扩大了其临床证据基础并提高了利用率。
其新的IRIDEX 532和577系统单点平台获得了美国食品药品管理局的批准,巩固了他们在视网膜治疗中的地位。
他们正在制定战略,以提高现有设备群的利用率,并提高中期青光眼患者的采用率。
2024年,随着业务流的改善和供应链问题的解决,该公司预计将恢复到更正常的水平。
随着视网膜领域的两个新平台的开发,该公司将自己定位为复苏,人们对新的IRIDEX PASCAL平台产生了浓厚的兴趣。
More details: IRIDEX IR
更多详情: IRIDEX IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。
译文内容由第三方软件翻译。